PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084843
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084843
Insulin Delivery Devices Market is estimated to be valued at USD 19.8 Bn in 2026 and is expected to reach USD 31.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 19.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 31.2 Bn |
Direct subcutaneous insulin injection are the most common form of drug delivery, using a needle and syringe. There are different types of insulin delivery devices available including, syringes, pens, jet injectors, and insulin pumps. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. However, several disposable and reusable pen devices have been developed that provide options for delivering rapid insulins and insulin premixes. Type or dosage of insulin can be changed according to the requirements to meet the individual needs of the patient Manufacturers are focusing on designing products, which are cost effective for people with diabetes which is expected to propel the growth of the insulin delivery devices market. For instance, in July 2017, Becton, Dickinson and Company launched BD Viva pen needles, have a highly engineered needle tip design for improved comfort and considered as the most cost-effective option for insulin-injecting people with diabetes in the UK.
The market is gaining significant traction due to increasing prevalence of diabetes, and new innovations in terms of design. According to the World Health Organization, in 2016, an estimated 422 million adults are living with diabetes globally. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to rising prevalence of obesity. However, high cost of some insulin delivery devices is expected to be a restraining factor for the market growth. For instance, insulin analogs supplied in cartridges or prefilled pens have a higher per unit of insulin cost than insulin analogs supplied in vials. For example, one vial (1000 U) of insulin costs US$ 105.95, which equates to a cost of 10.6 cents per unit of insulin. Five prefilled insulin pens containing insulin glulisine (total of 1500 U) have a total cost of US$ 201.01, equating to a cost of 13.4 cents per unit of insulin (26% over the cost of insulin glulisine supplied in a vial).